Key facts
- Boltz’s last known valuation is $130.0M (Jan 2026).
- It has raised $28.0M; the latest was Seed Round ($28.0M) in Jan 2026.
- Notable investors include Andreessen Horowitz, Amplify Partners, Obvious Ventures, Clément Delangue, Factorial Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Boltz
- ·The full record, as it builds
Funding rounds
No funding rounds for Boltz are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Boltz
Operator of an AI-based biotechnology company designed to accelerate drug discovery from hit identification to lead optimization. The company's platform defines and refines the biological targets with AI assistance, runs large-scale screening across distributed infrastructure, and integrates experimental data to continuously improve results, enabling users to get AI-powered drug discovery platform and simplify their operation.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 15
- Website
- boltz.bio/
- Ownership
- Privately Held (backing)
Boltz doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Boltz shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Boltz in its N-PORT filings yet. We sweep new filings monthly.